Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07424833 · ClinicalTrials.gov registry record · Phase 1
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
A Phase 1 study, sponsored by Ascentage Pharma Group.
- Not yet
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT07424833 is a Phase 1 study that has not yet begun recruiting, run by Ascentage Pharma Group. The registered enrollment target is 180 participants.
The verdict
NCT07424833, a Phase 1 study, has not yet begun recruiting, sponsored by Ascentage Pharma Group.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
Interventions
- DRUG APG-3288
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-03 |
| Est. Completion | 2031-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07424833
The ClinicalTrials.gov registry entry for NCT07424833 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APG-3288 is the first listed.
NCT07424833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07424833 about?
NCT07424833 is a clinical study titled "A Study of APG-3288 in Relapsed/Refractory Blood Cancers". This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
What is the current status of trial NCT07424833?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2026-03. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07424833?
The interventions under investigation include: APG-3288 (DRUG).
Who is sponsoring clinical trial NCT07424833?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.